Moleculin Biotech Published Cardiac Safety Findings

A new peer-reviewed analysis suggests the drug Annamycin shows no evidence of dose-dependent cardiotoxicity.

Updated on Sept. 28, 2026 in Heart Disease

Bold flat-color editorial illustration featuring a glass vial and pipette, representing biopharmaceutical cardiac safety research. — Moleculin Biotech reported that its drug candidate Annamycin showed no evidence of dose-dependent cardiotoxicity in a recent peer-reviewed analysis of five clinical trials. AI Illustration. Upload story photo >

Live Poll

Does evidence of improved safety in drug trials increase your trust in new medical treatments?

Moleculin Biotech released a peer-reviewed cardiac safety analysis of its drug candidate, Annamycin, in Frontiers in Cardiovascular Medicine. The report concludes there was no statistically significant impact on heart function among patients treated across five clinical trials.

Why it matters

Traditional anthracyclines are limited in medical use by cumulative, dose-dependent cardiotoxicity. This new data suggests that Annamycin may avoid these common heart-related side effects, potentially offering a safer alternative for patients.

The analysis reviewed 90 patients treated across trials for acute myeloid leukemia and metastatic soft tissue sarcoma with a median cumulative dose of 660 mg/m². Serial ECGs, cardiac biomarkers, and longitudinal strain assessments showed no significant cardiotoxicity.

The players

Moleculin Biotech

This Houston-based clinical-stage pharmaceutical company develops therapies for cancer patients.

Cleveland Clinic

This major academic medical center provided an independent evaluation of the cardiac safety findings.

The details

Researchers conducted a pooled analysis of safety data from five sponsor- and investigator-initiated clinical trials to monitor cardiac function. An independent cardio-oncology laboratory at the Cleveland Clinic verified the findings, reporting no association between cumulative exposure or patient age and changes in ejection fraction.

September 28, 2026: Moleculin Biotech announced the publication of the peer-reviewed study.

The Big Picture

This publication provides critical safety validation for the ongoing progress of the MIRACLE clinical development program. By establishing a lack of cardiotoxicity, the researchers clear a major regulatory and clinical hurdle for the development of new cancer therapies.

This research provides patients and providers with increased assurance regarding the safety profile of a potential new chemotherapy option. By potentially reducing the risk of heart damage, this development could improve long-term wellness for individuals undergoing aggressive cancer treatment.

The takeaway

The successful safety analysis highlights the importance of developing oncology treatments that specifically target disease without compromising cardiovascular health. Patients should consult their oncologists to understand how these findings might influence future treatment options as clinical trials proceed.

What happens next

Moleculin Biotech will continue to evaluate Annamycin in the ongoing MIRACLE clinical development program for patients with relapsed or refractory acute myeloid leukemia.